Previous editions of BioBucks

Plus a first-in-class herpes approval, an alpha-emitter Phase 3 win, and three biotechs queuing for IPOs.

Plus Zealand’s amylin data in diabetes, Tukysa moves up a line, and TRexBio prices at $14.

Plus Halozyme blocks SC Keytruda in eight countries, and Caribou pulls the plug.

Plus Epkinly's frontline DLBCL win and ArriVent's 57% plunge.

Vaxcyte's pivotal print sent PCVX flying, Shionogi paid $2B for IntraBio, and Genentech bought Alector a runway.

Lilly takes Jaypirca first-line, and a sell-side desk crowns Genmab’s ovarian ADC.

Survodutide wins Phase 3 and still disappoints, while Lilly walks away from Foghorn.

Plus Lilly's amylin cocktail edges its own triple-G, and a liver death shadows Bristol's fibrosis bet.

Year-four Huntington's data wobbles, full TRIUMPH-2 lands at EASD, and Merck's TL1A clears HS.

Merck's split-screen Monday, and Novo pays $300M upfront for a weekly GLP-1 pill.

Novo licenses monthly-shot tech, Merck's kidney doublet beats its PDUFA, EASD opens in Milan.

Merck's $3B eye bet clears its pivotal test, Lilly's weekly insulin lands, Overton parries.

Enveda banks $311M at a ~$2B valuation, and Roche's monthly IgAN shot hits in Phase 3.

Celldex's hives double comes with an anaphylaxis asterisk, and Amgen squeezes a Phase 3 win out of Horizon.

FDA staff go easy on Galleri, Pfizer's MFN fine print leaks, and Bayer sells Stivarga.

Xenon sheds 23% on a psychiatry pause, and Beacon lands the first pivotal win in XLRP.

Ultragenyx wins full approval two days early, and Roche buys 300,000 shots on goal.

A TREM2 flop, a brain-shuttle cheque, and two years of kidney receipts from Vera.

Plus Curium's first Lutathera lookalike, TrialBlazer opens, and J&J's depression drug misses again.

A CTLA-4 doubles survival in squamous lung, and Apollo circles DePuy Synthes.

GSK and Roche land matching survival wins in Seoul; Etcamah flunks first-line breast.

Plus a top-20 Novartis holder wants a board shake-up, and AbbVie finds a migraine niche.

Bayer takes first-line HER2 lung, Solstice debuts big, and WCLC is two days out.

A survival win, a 10% drawdown, and an oral HAE drug at 83%.

Novo scraps two more ziltivekimab trials, and FDA approves a drug off a blood test.